MapLight Raises $150 Million as Schizophrenia Drug Development Broadens

Fresh capital follows positive Phase 2 data for ML-007C-MA as drug developers target cognition, negative symptoms and treatment adherence.

Schizophrenia remains one of psychiatry’s most difficult diseases to treat. Antipsychotic drugs can control hallucinations, delusions and other positive symptoms, but patients can also struggle with cognitive impairment, social withdrawal, reduced motivation and the challenge of staying on treatment over time.

A new generation of drug development is increasingly targeting those gaps. And on Thursday, MapLight Therapeutics (NASDAQ: MPLT) put another $150 million behind its effort.

MapLight Funds the Next Stage

MapLight announced a private placement expected to generate approximately $150 million in gross proceeds, with the financing expected to close August 14. The company plans to use the capital primarily to advance ML-007C-MA, including its Phase 3 schizophrenia program and ongoing VISTA Phase 2 study in Alzheimer’s disease psychosis.

The financing follows positive Phase 2 ZEPHYR results reported in July. The 210/3 mg twice-daily dose of ML-007C-MA met the primary endpoint, producing a statistically significant improvement in PANSS total score versus placebo at Week 5, with an effect size of 0.37 and a 4.5-point difference versus placebo.

The study also produced a potentially important signal in cognition. Among participants with baseline cognitive impairment, ML-007C-MA showed a statistically significant improvement on a prespecified cognitive endpoint, with an effect size of 0.51. MapLight said that improvement appeared independent of the change in psychotic symptoms.

The company plans to advance ML-007C-MA into an additional registrational study in schizophrenia.

Different Approaches to the Same Disease

MapLight is part of a broader effort to address different limitations of schizophrenia treatment.

Teva Pharmaceutical Industries (NYSE: TEVA) is focused in part on treatment duration and adherence. Its approved UZEDY formulation of risperidone is administered by subcutaneous injection once every one or two months. Teva is also advancing TEV-‘749, a once-monthly extended-release injectable formulation of olanzapine through regulatory review.

Teva has expanded its approach beyond medication as well. In April, it launched Home Ground, an online resource designed with people living with schizophrenia and care partners, offering tools and community support around symptom management, emotional wellness, independent living and physical health.

Vanda Pharmaceuticals (NASDAQ: VNDA) added another treatment option in February when the FDA approved BYSANTI (milsaperidone) for schizophrenia in adults and acute manic or mixed episodes associated with bipolar I disorder.

Minerva Neurosciences (NASDAQ: NERV) is pursuing a different part of the disease altogether. Its Phase 3 candidate roluperidone is being developed specifically for the negative symptoms of schizophrenia, such as diminished motivation, emotional expression and social engagement.

Minerva’s confirmatory Phase 3 C19 study is designed to enroll 380 patients, with topline efficacy results from its initial 12-week phase expected in the second half of 2027. The company says roluperidone remains the only late-stage candidate specifically targeting negative symptoms.

What Investors Are Watching

The emerging schizophrenia pipeline increasingly reflects the complexity of the disease itself.

MapLight is investigating psychosis and cognition through a muscarinic approach. Teva is developing longer-acting formulations that could address adherence. Vanda has introduced a newly approved treatment, while Minerva is targeting negative symptoms that existing antipsychotics often leave unresolved.

For MapLight, the $150 million financing shifts attention back to execution. The next question is whether the efficacy seen in ZEPHYR can be replicated in Phase 3 and whether its cognitive signal holds up as development advances.

That broader shift may be the more important story: schizophrenia drug development is moving beyond controlling psychosis toward addressing more of the disease’s full burden.